This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
Melan-A VHH-8His-Cys-tag Recombinant Alpaca Monoclonal Antibody (SAA1259)
catalog :
MA5-54638
quantity :
100 ug
price :
US 429.00
clonality :
recombinant
host :
alpaca
conjugate :
nonconjugated
clone name :
SAA1259
reactivity :
human
product information
Product Type :
Antibody
Product Name :
Melan-A VHH-8His-Cys-tag Recombinant Alpaca Monoclonal Antibody (SAA1259)
Catalog # :
MA5-54638
Quantity :
100 ug
Price :
US 429.00
Clonality :
Recombinant Monoclonal
Purity :
Metal-chelate chromatography
Host :
Alpaca
Reactivity :
Human
Applications :
ELISA: Assay-dependent
Species :
Human
Clone :
SAA1259
Isotype :
VHH
Storage :
Store at 4 C short term. For long term storage, store at -20 C, avoiding freeze/thaw cycles.
Description :
MART1 is involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.
Immunogen :
Recombinant Human MLANA.
Format :
Liquid
Applications w/Dilutions :
ELISA: Assay-dependent
Aliases :
A930034P04Rik; Antigen LB39-AA; antigen SK29-AA; MART1; MART-1; melan-A; melanoma antigen recognized by T-cells 1; melanoma associated antigen recognized by T-cells 1; MLANA; Protein Melan-A
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments